Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 6/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15096107 | 0.83 | NR1I2 (0.43) | CFTRHDAC10HDAC6NR1I2DNM1 | |
| SCHEMBL23278436 | 0.74 | CFTR (0.40) | CFTR | |
| SCHEMBL15096108 | 0.73 | CFTR (0.43) | CFTR | |
| SCHEMBL14845721 | 0.73 | CFTR (0.41) | CFTR | |
| SCHEMBL12745363 | 0.73 | NR1I2 (0.43) | CFTRHDAC10HDAC6NR1I2DNM1 | |
| SCHEMBL13365257 | 0.72 | CFTR (0.51) | CFTRHDAC10HDAC6NR1I2 | |
| SCHEMBL20808194 | 0.71 | CFTR (0.46) | CFTR | |
| SCHEMBL12745368 | 0.67 | NR1I2 (0.42) | CFTRHDAC10HDAC6NR1I2DNM1 | |
| SCHEMBL14845741 | 0.67 | CFTR (0.41) | CFTRNR1I2 | |
| SCHEMBL12827355 | 0.65 | HDAC10 (0.39) | CFTRHDAC10HDAC6NR1I2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10987348-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987348-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | CFTR 1/4885HDAC10 2755/4885HDAC6 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.